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LETTER TO THE EDITOR
DT-Diaphorase: questionable role in mitomycin C resistance, but a target
for novel bioreductive drugs?
Sir- Marshall et al. (1989) reported recently that a human
fibroblast cell line from a member of a cancer-prone family
(3437T) was six times more resistant than an equivalent cell
line from a normal donor (GM38) to the bioreductive anti-
tumour antibiotic mitomycin C. Interestingly, this resistance
was seen only when the drug exposure was carried out under
well oxygenated conditions, but not under hypoxic conditions
(< 10 p.p.m. 02)- Similarly, a Chinese hamster ovary cell line
with induced resistance to mitomycin C under oxic con-
ditions did not exhibit comparable resistance under hypoxic
conditions (Hoban et al., 1989).
Compared to the normal human fibroblast line GM38,
Marshall et al. (1989) reported that the resistant 3437T cell
line exhibited substantially reduced levels of the enzyme DT-
diaphorase or NAD(P)H: (quinone-acceptor) oxidoreductase
(E.C.1.6.99.2) (Ernster et al., 1987). Also, the DT-diaphorase
inhibitor dicoumarol (3,3'-methylene-bis [4-hydroxycoumar-
in]) was shown to decrease the aerobic sensitivity of the
normal GM38 line but not the resistant 3437T line. The
conclusion was drawn that DT-diaphorase may play an im-
portant role in the bioreductive activation of mitomycin C
under oxic conditions, and that deficient expression of this
enzyme by the 3437T cell line leads (at least in part) to
aerobic resistance to the drug. Similarly, this resistance is
mimicked to some extent in the normal GM38 line by
dicoumarol inhibition of the enzyme.
A number of studies on the mechanism of action of mito-
mycin C have relied heavily on the use of dicoumarol as a
specific inhibitor of DT-diaphorase to probe for the func-
tional role of this enzyme (e.g. Keyes et al., 1984, 1985a, b;
Dulhanty et al., 1989). In one series of studies, the intriguing
result was obtained that dicoumarol was able to increase the
sensitivity of EMT6 mouse mammary tumour cells to mito-
mycin C under hypoxic conditions, yet decreased the sen-
sitivity of the same cells when exposed to the drug under oxic
conditions (Keyes et al., 1984, 1985a, b). The increased tox-
icity under hypoxic conditions was related to the stimulation
by dicoumarol of the amount of alkylating species generated
(Keyes et al., 1984). The clear and reasonable implication at
the time the studies were conducted was that DT-diaphorase
activates mitomycin C in air but serves to detoxify the same
drug under hypoxia.
The proposed role for DT-diaphorase in the toxification of
mitomycin C under aerobic conditions is contradictory to
that which is generally thought to apply for simple quinones
such as menadione (Lind et al., 1982; Thor et al., 1982;
Morrison et al., 1984; Ernster et al., 1987). The aerobic
toxicity of such compounds arises via one-electron reduction
to the semiquinone free radical by enzymes such as
NADPH:cytochrome P-450 reductase, leading to production
of toxic oxygen species by auto-oxidation in a futile cycle
(Figure 1). These radicals cause DNA and membrane dam-
age. Since DT-diaphorase is an obligatory two-electron
donor (lyanagi & Yamazaki, 1970), reduction of quinones by
this enzyme bypasses the toxic semiquinone radical by direct
formation of the relatively stable hydroquinone, which can
then undergo conjugation (Figure 1). Thus under aerobic
conditions DT-diaphorase plays an important role in the
cellular defense against oxygen stress caused by simple quin-
ones, and inhibition by dicoumarol gives rise to increased
toxicity (see Ernster et al., 1987).
The picture is of course more complex with mitomycin C
since toxicity under oxic conditions will arise not only via
oxidative stress (Bachur et al., 1979; Pritsos & Sartorelli,
1986) but also through bioreductive activation to DNA-
alkylating species (Pan et al., 1984; Tomasz et al., 1987).
Under hypoxic conditions DNA adducts, including cross-
links, will predominate. It has been argued that both one-
electron and two-electron reduction will result in bioreductive
alkylation (Tomasz et al., 1987; Hoey et al., 1988). Never-
theless, the precise role of these two reduction mechanisms in
this toxic pathway remains unclear.
Further complications to the ongoing controversy are sug-
gested by correlations between DT-diaphorase activity and
cytotoxicity obtained in two other recent studies. Pritsos et
al. (1987) compared DT-diaphorase in three xenograft
tumours grown in nude mice (human, equine and canine
neoplasms) and found the lowest enzyme activity in the
tumour with the greatest mitomycin C sensitivity. In addi-
tion, in vivo treatment of the sensitive tumour with
mitomycin C resulted in a higher level of enzyme activity in
the subsequently regrowing tumours. These correlations are
consistent with a detoxifying function for DT-diaphorase in
vivo. On the other hand, in the previously mentioned study of
a Chinese hamster ovary cell line with induced resistance
through exposure to mitomycin C under aerobic conditions
in vitro, there was no measureable DT-diaphorase activity
but a decrease in NADPH: cytochrome P-450 reductase
(Hoban et al., 1989; Walton et al., 1989). These results
indicate a more predominant role for cytochrome P-450
reductase in governing mitomycin C sensitivity. This enzyme
is known to metabolise mitomycin C (Bachus et al., 1979).
Much of the evidence in the continuing debate of the role
of DT-diaphorase in mitomycin C bioactivation comes from
studies such as those discussed earlier utilising dicoumarol as
an inhibitor of the enzyme. There has, however, always been
some concern regarding the over-reliance on dicoumarol as a
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Figure 1 Predominant roles of enzymatic one-electron versus
two-electron transfer in the toxification versus detoxification reac-
tions of simple quinones such as menadione. According to this
scheme one-electron transferring enzymes such as NADPH:
cytochrome P-450 reductase catalyse the formation of the semi-
quinone free radical, leading to the generation of the toxic species
superoxide in the presence of oxygen. This pathway is bypassed
as a result of direct two-electron reduction via DT-diaphorase,
forming the more stable hydroquinone which can be further
detoxified via conversion by conjugating enzymes to water sol-
uble glucuronides and sulphates for excretion.
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putative inhibitor of mitomycin C metabolism by DT-dia-
phorase where the measured end-point is cytotoxicity and not
modulation of bioreductive metabolism. The potential for
dicoumarol to modify cytotoxicity via additional mechanisms
is clear (Keyes et al., 1987; Akman et al., 1985). In partic-
ular, dicoumarol was shown to increase hypoxic mitomycin
C toxicity (but not reduce oxic toxicity) in L1210 cells with
measurable DT-diaphorase activity (Keyes et al., 1987). Po-
tentiation of menadione toxicity in L1210 cells by a method
not involving DT-diaphorase has also been proposed (Ak-
man et al., 1985). Indeed the authors of the various papers
cited above, including Marshall et al. (1989), have been
appropriately cautious in pointing out the potential artefacts
of this approach.
In view of the contentious role of DT-diaphorase in mito-
mycin C toxicity, it is surprising that until recently there has
been no published attempt to demonstrate metabolism of the
drug by the purified enzyme. Such studies have now been
carried out with several enzyme preparations and the results
directly contradict a role for the enzyme in modulating
mitomycin C sensitivity and resistance. The drug acts not as
a substrate but in fact as an inhibitor of DT-diaphorase
purified from human kidney by affinity and hydroxyapatite
chromatography. This was demonstrated initially by two of
us (Schlager & Powis, 1988) and confirmed independently by
the others (Walton & Workman, unpublished). Mitomycin C
is also not a substrate for DT-diaphorase purifed from rat
liver (Powis & Schlager, unpublished). In addition, no
dicoumarol-inhibitable metabolism of mitomycin C could be
identified in DT-diaphorase-rich preparations obtained from
the Chester Beatty strain of the rat Walker tumour (see later)
or the HT29 human colon carcinoma (Walton & Workman,
unpublished). In all cases the most direct assay involved
analysis of mitomycin C using a sensitive and specific high-
performance liquid chromotography assay, and we can now
define the lower limit of measurable activity as
<30 pmol min-' Unit' enzyme at 50 gM mitomycin C
(where 1 Unit = 1 limol cytochrome c reduced per min). As a
positive control, we confirmed the observation of the reduc-
tion of 2,5-diaziridinyl-3,6-bis-(carboethoxyamino)-1,4-benzo-
quinone (AZQ) by HT29 cells (Siegel et al., 1989) and also
by Walker cells. Analogous to these findings was the demon-
stration that another complex quinone antitumour antibiotic,
doxorubicin, was likewise not a substrate for rat liver DT-
diaphorase (Wallin, 1986). On the other hand, Pritsos et al.
(1987) claimed that mitomycin C was a substrate for partially
purified beef liver DT-diaphorase with a Km of 1.5ZlM, al-
though the assay method and detailed data were not present-
ed.
DT-diaphorase exists in multiple forms (Ernster et al.,
1987) and it is conceivable that some forms but not others
are able to bioactivate or detoxify mitomycin C. It is also
possible that mitomycin C is metabolised by DT-diaphorase
at a rate below the lower limit of analytical detection, but
sufficient for biological activity. However, in view of the
apparent inability of the human kidney, HT29 colon car-
cinoma and rat Walker tumour enzymes to metabolise
mitomycin C as well as the potential for dicoumarol to
exhibit pleiotropic pharmacological effects, we believe that
evidence of dicoumarol modulation of cytotoxicity alone
should no longer be accepted as evidence for the participa-
tion of DT-diaphorase in the bioactivation of this drug.
Direct metabolic and enzymological data should be sought to
complement such cytoxicity studies, so that the true role, if
any, of DT-diaphorase in the metabolism of mitomycin C
and related quinones can be definitively identified.
Should DT-diaphorase from a variety of sources fail to
metabolise mitomycin C, it will be important to establish
whether altered expression or activity ofthis enzyme is involved
in other ways in the control ofmitomycin C toxicity, or whether
this is an epiphenomenon. It is interesting to note that rodent
liver DT-diaphorase expression can be upregulated by two
classes of xenobiotic inducers: (1) those such as polycyclic
aromatics acting via the Ah locus and causing a simultaneous
increase in phase 1 enzymes including cytochrome P1-450; and
(2) an alternative group including tert-butylhydroquinone and
redox-labile diphenols capable of inducing phase 2 enzymes,
such as UDPG-glucuronyl transferases, which normally play a
detoxication role (see De Longetal., 1987). DT-diaphorase has
been shown to exhibit co-ordinately increased level ofmRNA
expression with glutathione-S-transferase Ya and Yb genes in
rat hepatic preneoplastic nodules induced during chemical
carcinogenesis in the Solt-Farber model, apparently as a result
of hypomethylation of the gene (see Pickett, 1987).
Exciting new possibilities have been revealed by the recogni-
tion of close similarities in the biochemical profiles of rat
preneoplastic and neoplastic hepatocytes and ofin vitro derived
multidrug resistant cells (Moscow & Cowan, 1988; Burt &
Thorgeirsson, 1988). In both situations resistance to a range of
toxins is seen; toxin accumulation is reduced; expression ofthe
P-170 drug efflux membrane glycoprotein increases; protective
phase 2 and related enzyme activities rise; and phase 1 enzymes
may fall or rise. Thus expression of these various genes may
depend on overlapping regulatory elements.
The role of DT-diaphorase in multidrug resistance is un-
known. No up-regulation was observed in a multidrug-
resistant MCF-7 human breast cancer line showing increased
expression of glutathione-S-transferase x and decreased aryl
hydrocarbon hydroxylase activity; in fact a decrease in DT-
diaphorase was seen (Vickers et al., 1989). However, protein
changes, including cytochrome P-450s, glutathione-S-
transferases and even P-glycoprotein, are by no means con-
sistent across all multidrug-resistant cell lines (neither is the
cross-resistance profile), and a range of lines should now be
examined to clarify this situation.
Increased expression of DT-diaphorase in tumour cells,
including human breast and colon tumours, may be quite
widespread (Koudstaal et al., 1975; Schor & Cornelisse, 1983;
Schor, 1987; Schlager & Powis, 1987, 1988). In view of these
general findings, the presence of high DT-diaphorase levels in
the HT29 human colon carcinoma and Walker 256 tumour cell
lines makes these tumours especially appropriate models. It is
interesting to note that the Chester Beatty strain ofthe Walker
256 rat tumour, though now an undifferentiated carcinosar-
coma, originally arose as a mammary carcinoma of typical
adenomatous structure (Earle, 1935; Rosenoer et al., 1966).
Despite the apparent inability to metabolise mitomycin C,
DT-diaphorase may represent an important target for drug
bioactivation. In support of this, the elegant recent work of
Knox et al. (1988a, b) has shown that high expression of
DT-diaphorase in the Chester Beatty Walker 256 rat
accounts for the extreme sensitivity of this tumour to CB
1954 (5-[aziridin-1-yl]-2,4-dinitrobenz-1-amide). DT-
diaphorase reduces this agent in air to a highly toxic 4-
hydroxylamine derivative. Moreover, we have recently shown
similar activity for purified human kidney DT-diaphorase,
and the Walker enzyme to have the ability to reduce the
novel benzotriazine di-N-oxide hypoxic cell cytotoxin SR
4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide) (unpublished
data).
In summary, DT-diaphorase appears to play a questionable
role in mitomycin C resistance, and further work is required to
resolve this issue. DT-diaphorase may, however, provide an
attractive target for the design of novel bioreductive drugs for
the treatment ofhuman tumours shown specifically to express
high levels or an unusual form of this intriguing enzyme.
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